The U.S. Food and Drug Administration (FDA) announced a revision to the Boxed Warning on the label for Metformin Hydrochloride, effective 2026-07-20. This update provides critical information regarding the risk of lactic acidosis, a severe and potentially fatal metabolic complication associated with metformin use.
Background
The Boxed Warning, also known as a black box warning, is the strongest warning that the FDA requires for prescription drugs. For Metformin Hydrochloride, this warning specifically addresses the risk of lactic acidosis. Postmarketing cases of metformin-associated lactic acidosis have been reported, resulting in serious outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The FDA emphasizes that the onset of metformin-associated lactic acidosis is often subtle, making early recognition challenging for clinicians.
What this means
This label revision underscores the importance for healthcare professionals to be vigilant for the signs and symptoms of metformin-associated lactic acidosis in patients. Given the subtle onset, clinicians should maintain a high index of suspicion, especially in patients with predisposing conditions. The updated warning aims to provide clearer guidance to mitigate the risks associated with this serious adverse event, reinforcing the need for prompt diagnosis and management to improve patient outcomes.
Source
This information was sourced from the FDA, detailing a label revision for Metformin Hydrochloride, effective 2026-07-20. The updated label can be accessed on dailymed.nlm.nih.gov.